Efficacy News and Research

RSS
BioMarin reports $0.5 million GAAP net loss for second-quarter 2010

BioMarin reports $0.5 million GAAP net loss for second-quarter 2010

OECD approves new, non-animal testing guideline for skin irritation

OECD approves new, non-animal testing guideline for skin irritation

U.S. gastroenterologists prescribe Abbott's Humira off-label for treating ulcerative colitis: Report

U.S. gastroenterologists prescribe Abbott's Humira off-label for treating ulcerative colitis: Report

Repligen receives three additional grants to develop HDAC inhibitors for neurodegenerative diseases

Repligen receives three additional grants to develop HDAC inhibitors for neurodegenerative diseases

Hangovers cost Australia an estimated $453 million: Study

Hangovers cost Australia an estimated $453 million: Study

Cell-of-origin for prostate cancer identified

Cell-of-origin for prostate cancer identified

Opinions: IDUs and HIV; AIDS 2010; International Violence Against Women Act

Opinions: IDUs and HIV; AIDS 2010; International Violence Against Women Act

Functional MRI can be used to assess tumor viability

Functional MRI can be used to assess tumor viability

Opportunity in European embolization coil market leads to major acquisitions in 2010: MRG

Opportunity in European embolization coil market leads to major acquisitions in 2010: MRG

FDA lifts hold, allows Geron to proceed with Phase I clinical trial of GRNOPC1 in spinal cord injury

FDA lifts hold, allows Geron to proceed with Phase I clinical trial of GRNOPC1 in spinal cord injury

Cerus second-quarter product revenue for INTERCEPT Blood System increases 47% to $5.7 million

Cerus second-quarter product revenue for INTERCEPT Blood System increases 47% to $5.7 million

New discovery may lead to effective targeted treatments for prostate cancer: UCLA

New discovery may lead to effective targeted treatments for prostate cancer: UCLA

Anthera initiates PEARL-SC Phase 2b study of A-623 for lupus

Anthera initiates PEARL-SC Phase 2b study of A-623 for lupus

Acura Pharmaceuticals reports net loss of $3.2M for second-quarter 2010

Acura Pharmaceuticals reports net loss of $3.2M for second-quarter 2010

Intra-Cellular Therapies ITI-007 Phase Ib/II clinical trial for schizophrenia meets primary endpoint

Intra-Cellular Therapies ITI-007 Phase Ib/II clinical trial for schizophrenia meets primary endpoint

ACADIA initiates new pimavanserin Phase III trial for Parkinson's disease psychosis

ACADIA initiates new pimavanserin Phase III trial for Parkinson's disease psychosis

Transforaminal injection of steroids is a viable alternative for lumbar radicular pain surgery

Transforaminal injection of steroids is a viable alternative for lumbar radicular pain surgery

ZOLL Medical receives PMDA approval to distribute AED Plus, AED Pro in Japan

ZOLL Medical receives PMDA approval to distribute AED Plus, AED Pro in Japan

ZOLL Medical revenues for third-quarter fiscal 2010 up 17% to $111.3 million

ZOLL Medical revenues for third-quarter fiscal 2010 up 17% to $111.3 million

Safeguard Scientifics second-quarter aggregate revenue of partner companies increase 47% to $91.6 million

Safeguard Scientifics second-quarter aggregate revenue of partner companies increase 47% to $91.6 million

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.